Cancer Disparities and Black American Representation in Clinical Trials Leading to the Approval of Oral Chemotherapy Drugs in the United States Between 2009 and 2019

Over the past 10 years, oral chemotherapy made up about half (45.6%) of all US Food and Drug Administration (FDA)–approved oncolytic and hematologic medications. Given the disparity in incidence and mortality rate because of certain cancers among Black Americans (BAs) in the United States, a review...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajewole, Veronica B., Akindele, Oyinkansola, Abajue, Uzoamaka, Ndulue, Okwuoma, Marshall, Jazzmin J., Mossi, Yhenew T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Special Series: Disparities in Cancer Care for Black People in the United States
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120664/
https://www.ncbi.nlm.nih.gov/pubmed/33974825
http://dx.doi.org/10.1200/OP.20.01108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120664/
https://www.ncbi.nlm.nih.gov/pubmed/33974825
http://dx.doi.org/10.1200/OP.20.01108

Ejemplares similares